NCT00087594View on ClinicalTrials.gov

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program.

PHASE4CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

October 31, 2006

Study Completion Date

October 31, 2006

Conditions
Hepatitis C, Chronic
Interventions
DRUG

peginterferon alfa-2a [Pegasys]

180 micrograms sc weekly for 24 weeks (G 2/3) or 48 weeks (G 1)

DRUG

ribavirin

1000/1200mg (\< or \>= 75 kg, respectively), po in two doses daily for 48 weeks (G 1) or 800 mg po in two doses daily for 24 weeks (G 2/3)

Trial Locations (7)

10003

New York

21205

Baltimore

23249

Richmond

60515

Downers Grove

94121

San Francisco

96813

Honolulu

06030

Farmington

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00087594 - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program. | Biotech Hunter | Biotech Hunter